Comparative Pharmacology
Head-to-head clinical analysis: NOVOLOG FLEXTOUCH versus NOVOLOG PENFILL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOVOLOG FLEXTOUCH versus NOVOLOG PENFILL.
NOVOLOG FLEXTOUCH vs NOVOLOG PENFILL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin analog with rapid onset and short duration of action; binds to insulin receptors, promoting cellular glucose uptake and inhibiting hepatic glucose production.
Insulin aspart is a rapid-acting recombinant human insulin analog. It lowers blood glucose by binding to insulin receptors on skeletal muscle and adipose tissue, promoting glucose uptake, and inhibiting hepatic glucose production via glycogenolysis and gluconeogenesis.
Subcutaneous injection; typical adult dose is 0.5-1 unit/kg/day divided into multiple doses; for type 1 diabetes, administered 5-10 minutes before meals with a basal insulin; for type 2 diabetes, initial dose 4 units or 0.1-0.2 units/kg with meals.
Subcutaneous injection: 0.5-1 unit/kg/day divided into multiple doses (e.g., basal-bolus regimen). Individualized based on glucose monitoring.
None Documented
None Documented
1.5-2 hours (subcutaneous); terminal elimination half-life: 1.8 hours
~5-7 minutes (free insulin aspart); clinical effect duration correlates with SC absorption half-life ~1-2 hours
Renal: ~60% as unchanged drug and metabolites; biliary/fecal: ~40%
Renal: 60-80% as metabolites; unchanged drug excreted minimally. Fecal: <10%
Category C
Category C
Insulin Analog
Insulin Analog